Glutamate is the most abundant excitatory neurotransmitter, present at the bulk of cortical synapses, and participating in many physiologic and pathologic processes ranging from learning and memory to stroke. The tripeptide, glutathione, is one-third glutamate and present at up to low millimolar intracellular concentrations in brain, mediating antioxidant defenses and drug detoxification. Because of the substantial amounts of brain glutathione and its rapid turnover under homeostatic control, we hypothesized that glutathione is a relevant reservoir of glutamate and could influence synaptic excitability. We find that drugs that inhibit generation of glutamate by the glutathione cycle elicit decreases in cytosolic glutamate and decreased miniature excitatory postsynaptic potential (mEPSC) frequency. In contrast, pharmacologically decreasing the biosynthesis of glutathione leads to increases in cytosolic glutamate and enhanced mEPSC frequency. The glutathione cycle can compensate for decreased excitatory neurotransmission when the glutamate-glutamine shuttle is inhibited. Glutathione may be a physiologic reservoir of glutamate neurotransmitter.

Glutathione | glutamate | neurotransmission | mEPSC | acivicin

Significance

Glutathione is a major antioxidant and redox regulator in cells. In addition to its essential roles in redox homeostasis, it functions as cofactors for a multitude of enzymes. We show here that the glutathione cycle molds the activity of synaptic glutamate, the major excitatory neurotransmitter in the central nervous system. Deficits in glutathione have been linked to multiple neurodegenerative and neuropsychiatric disorders. Accordingly, agents that restore glutathione-glutamate homeostasis may afford therapeutic benefit.

Author contributions: T.W.S., B.D.P., S.H.S., and A.S. designed research; B.D.P., G.M.P., L.D.H., A.M.S., and Y.T. performed research; T.W.S., B.D.P., A.K., and A.S. contributed new reagents/analytic tools; T.W.S., B.D.P., S.H.S., and A.S. analyzed data; and T.W.S., B.D.P., S.H.S., and A.S. wrote the paper.

Reviewers: S.A.L., The Scripps Research Institute; and J.S.S., Case Western Reserve University.

The authors declare no conflict of interest. Published under the PNAS license.

1T.W.S. and B.D.P. contributed equally to this work.
2To whom correspondence may be addressed. Email: tsedlak@jhmi.edu or ssnyder@jhmi.edu.
3Present address: Department of Radiology, University of Pennsylvania, PA 19104.
4Present address: Weill Cornell Medicine, Cornell University, New York, NY 10065.

This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10.1073/pnas.1817851116/-/DCSupplemental.

Published online January 28, 2019.
levels and decreases glycine-cysteine, which is the source of rate-limiting cysteine in the intracellular synthesis of glutathione (21). As we had previously demonstrated in cell lines (16), total glutamate and glutathione levels declined in primary cortical neurons treated with acivicin (SI Appendix, Figs. S2 A and B). To confirm the specificity of this effect, shRNA targeting of GGT also decreased glutamate levels (SI Appendix, Fig. S2C). As an additional test of the specificity of the effect, we find that the decrease in glutamate brought by acivicin could be rescued by administration of pyroglutamate (5-oxoprolinolase, a downstream metabolite in the glutathione pathway that is a precursor of glutamate (SI Appendix, Fig. S1)). Pyroglutamate restores glutamate and presynaptic drive (see also SI Appendix, Fig. S2A) (n.s., not significant). Cumulative probability plots of mEPSC amplitude. Acivicin decreased mEPSC amplitude to a smaller degree than frequency. (‡P < 0.01, ‡‡P < 0.0001 by Steel-Dwass all pairs test.)

To determine if glutamate availability from the glutathione cycle (Fig. 1A) could shape excitatory transmission, we measured the frequency of miniature excitatory postsynaptic currents (mEPSCs), a reflection of presynaptic drive. Acivicin treatment (24 h) significantly decreased mEPSC frequency (Fig. 1 B, C, and E) and amplitudes to a smaller degree (Fig. 1 B, D, and F). To demonstrate specificity of the effect, we sought to rescue the decreased mEPSC frequency by pretreating with pyroglutamate (PGA) (Fig. 1A). Pyroglutamate rescued the effect on mEPSC frequency (Fig. 1 C and E) but not amplitude, consistent with it being a presynaptic precursor of glutamate. As we previously demonstrated, acivicin treatment at these concentrations did not elicit significant oxidative stress or affect cell viability (16).

**Inhibition of Glutamate Cysteine Ligase Depletes Neuronal Glutathione, Elevates Glutamate, and Increases Excitatory Neurotransmission.** Glutamate cysteine ligase (GCL) is the rate-limiting step for glutathione synthesis and utilizes glutamate as a substrate. Inhibition of GCL with BSO depleted glutathione rapidly, reflecting its short half-life (1–4 h) as a substrate of multiple enzymes (SI Appendix, Fig. S3B). BSO treatment increased neuronal glutamate (SI Appendix, Fig. S3A), consistent with our prior findings in cell lines (16). This was confirmed by shRNA to GCLC, the target of BSO, which increased glutamate levels (SI Appendix, Fig. S3C). To further test the role of GCL in modulating glutathione and glutamate, we utilized sulforaphane, which increases GCL expression through activation of the Nuclear factor-erythroid 2 p45-related factor 2 (Nrf2) pathway (22). While BSO inhibition of GCL decreased glutathione and increased glutamate, sulforaphane had reciprocal effects: It induced GCL and decreased glutamate while increasing glutathione (SI Appendix, Fig. S3 D–F). We previously demonstrated that these doses and durations of treatment do not cause detectable changes in oxidative stress or neuronal viability (16). BSO was utilized to test whether increasing the liberation of glutamate from the glutathione cycle could shape excitatory transmission. The BSO-induced increase in glutamate was accompanied by an increase in mEPSC frequency (Fig. 2 B, C, and E) and a smaller increase in amplitude (Fig. 2 B, D, and F).

**The Glutathione Cycle Can Complement the Glutamate-Glutamine Shuttle and Influence Excitatory Neurotransmission Under Conditions of Glutamine Restriction.** The glutamate-glutamine shuttle (SI Appendix, Fig. S4) between neurons and glia contributes 50–60% of a glutamate neurotransmitter (12, 13, 23) with intracellular sources such as glycolysis supplying the remainder. In the shuttle, glutamate is converted to glutamine in astrocytes, and then imported by neurons by system A transporters, where it is converted to glutamate intracellularly by phosphate-activated glutaminase (24). However, glutaminase knockout mice (25) or blockade of system A transporters with methylaminosobutyric acid (MeAIB) (15) fail to block excitatory neurotransmission. We explored whether the glutathione cycle can complement the actions of the glutamate-glutamine shuttle by blocking import of glutamine by the system A transporter.
Glutamate or glutathione synthesis increases it (16). We now report increased intracellular glutamate, whereas decreasing utilization of the liberation of glutamate from the glutathione cycle lead to decreased mEPSC frequency brought by MeAIB (Fig. 4 E). Decreasing the release of glutamate from the glutathione cycle by blocking GGT leads to diminished mEPSC. We demonstrated specificity of the effect of acivicin, which decreases glutamate liberation from glutathione, by rescuing with pyroglutamate, the immediate metabolic precursor of glutamate in the glutathione cycle. We have previously demonstrated that these fluxes of cytosolic glutamate can occur without significant increases in oxidative stress or altered cell viability (16). Thus, the glutathione pathway is poised to contribute glutamate without impacting neuronal viability unless there are massive, sustained deficits (16, 26). Our studies also reveal a modest effect of glutathione cycle inhibitors on mEPSC amplitude, implying possible postsynaptic effects. These could include an increase in the number or activity of postsynaptic receptors or may reflect increases in the number of neurotransmitter (glutamate) molecules or vesicles. While changes in mEPSC amplitude are often postsynaptically driven, increases in cytoplasmic glutamate can increase mEPSC amplitude, while decreased filling of vesicles decreases mEPSC amplitude (27–30). Another mode by which GSH could potentially modulate neurotransmission is by its effects on redox-regulated presynaptic proteins such as synaptosomal-associated protein 25 (SNAP-25) and N-ethylmaleimide-sensitive factor (NSF) (31, 32). Glutathione has also been reported to modulate the redox-sensitive site of NMDA receptors (33). These changes could be operational in neurodegenerative diseases, reflecting an imbalance in redox balance modulated by GSH. The redox effects of thiol compounds have also been reported to modulate the redox-sensitive site of NMDA receptors (33). These changes could be operational in neurodegenerative diseases, reflecting an imbalance in redox balance.

Discussion

We previously reported that the glutathione cycle may serve as a reservoir of total neuronal glutamate (16). Treatments that decrease the liberation of glutamate from the glutathione cycle lead to decreased intracellular glutamate, whereas decreasing utilization of glutamate or glutathione synthesis increases it (16). We now report that shunting of glutamate derived from glutathione can shape excitatory neurotransmission. Inhibiting GCL, which utilizes glutamate to synthesize glutathione, leads to increased glutamate and mEPSC frequency. Decreasing the release of glutamate from the glutathione cycle by blocking GGT leads to diminished mEPSC. We demonstrated specificity of the effect of acivicin, which decreases glutamate liberation from glutathione, by rescuing with pyroglutamate, the immediate metabolic precursor of glutamate in the glutathione cycle. We have previously demonstrated that these fluxes of cytosolic glutamate can occur without significant increases in oxidative stress or altered cell viability (16). Thus, the glutathione pathway is poised to contribute glutamate without impacting neuronal viability unless there are massive, sustained deficits (16, 26). Our studies also reveal a modest effect of glutathione cycle inhibitors on mEPSC amplitude, implying possible postsynaptic effects. These could include an increase in the number or activity of postsynaptic receptors or may reflect increases in the number of neurotransmitter (glutamate) molecules or vesicles. While changes in mEPSC amplitude are often postsynaptically driven, increases in cytoplasmic glutamate can increase mEPSC amplitude, while decreased filling of vesicles decreases mEPSC amplitude (27–30). Another mode by which GSH could potentially modulate neurotransmission is by its effects on redox-regulated presynaptic proteins such as synaptosomal-associated protein 25 (SNAP-25) and N-ethylmaleimide-sensitive factor (NSF) (31, 32). Glutathione has also been reported to modulate the redox-sensitive site of NMDA receptors (33). These changes could be operational in neurodegenerative diseases, reflecting an imbalance in redox balance modulated by GSH. The redox effects of thiol compounds have also been analyzed in modulation of GABA- and glycine-evoked currents in rat retinal ganglion cells (34). In addition to effects on redox-modulated synaptic proteins, depletion of GSH can alter steady-state nitrosylation (35). More generally, GSNO is a major source of NO bioactivity in the brain and its depletion will inhibit the activity of GSNO resulting in increased nitrosylation (nitrosative stress) (36, 37) and possibly altered neurotransmission. Further studies on the potential redox
effects of GSH need to be conducted to ascertain whether this aspect plays a role in neurotransmission. The glutathione pathway may also supply glutamate when glia-derived glutamine is blocked by MeAIB, which inhibits system A transporters. While glia-derived glutamine provides 50–60% of a glutamate neurotransmitter, when the pathway is blocked with MeAIB, excitatory transmission abruptly decreases but rapidly recovers, consistent with endogenous neuronal sources of glutamate neurotransmitter (15). We suggest glutathione is one such endogenous source, as impairing glutamate liberation from the cycle further diminishes synaptic activity by MeAIB, while increasing glutamate availability can rescue the impairment by MeAIB. A reservoir capacity of glutathione may be utile during periods of sustained synaptic activity. Future studies on the readily releasable glutamate pool in the presence of the GSH-glutamate cycle inhibitors would yield a more detailed picture of glutamate dynamics. The rapidly releasable pool is the maximum number of vesicles that can be released in 2 or 3 s and is thought to coincide with those vesicles that are docked to the active zone and primed for release. They may represent the pool of glutamate most recently recruited for neurotransmission and could be relevant to the present study involving acute effects of drugs affecting the GSH-glutamate cycle. Whole-cell recording techniques using methods described previously may be utilized to estimate the readily releasable pool size can be measured here after manipulating GSH-associated enzymes (38).

Alterations in neuronal glutamate levels, such as by fluxes to and from a glutathione reservoir, might have an impact upon glutamate neurotransmitter. Vesicular glutamate transporters have a much lower affinity for glutamate 0.5–3.5 mM than plasma membrane transporters GLT1/EAAAT2, whose $K_m$ is 4–40 μM (39, 40). Furthermore, as glutamate neurotransmitter typically does not saturate postsynaptic receptors, modest impacts upon release frequency may influence synaptic strength (27, 29, 41, 42). “Phasic” axons that fatigue in their glutamate neurotransmitter release have lower glutamate levels than “tonic” glutamate axons with greater glutamate levels (43). Glutamine levels are similar in both, suggesting that nonsoma areas contain more glutathione (44). Interestingly, our studies reveal the presence of the enzyme GGT in synaptosomes, suggesting that there may be accentuated exchange of glutathione to glutamate near vesicles (SI Appendix, Fig. S5). Metabolic flux analysis would yield additional information regarding flux of glutathione and glutamate under various conditions.

These findings may be relevant to human disease. Glutamatergic dysfunction has been implicated in schizophrenia by multiple lines of evidence (45–52). Several investigators have reported aberrant glutathione levels in schizophrenia patients, including medication naive subjects (53–57). Mice lacking the modifier subunit of GCL have a 60% reduction in glutathione, accompanied by abnormal cortical gamma synchrony, decreased parvalbumin interneurons, and behavioral phenotypes relevant to schizophrenia (58–60). Despite substantial glutathione deficits, the mice are outwardly healthy. Additionally, rare deficiencies of glutathione cycle enzymes (gamma-glutamylcysteine ligase, glutathione synthetase, 5-oxoprolinase, and gamma-glutamyl transferase) have all been associated with neuropsychiatric and cognitive impairments, although detailed phenomenological characterization has not been reported (9, 61, 62). A role for glutathione as a glutamate reservoir may be a bridge between distinct lines of research that implicate glutamatergic dysfunction and aberrant glutathione levels in neuropsychiatric conditions such as schizophrenia.

Fig. 3. The glutathione cycle supports excitatory transmission, but to a smaller degree than glutamine-derived glutamate. (A) Scheme of glutamate-glutamine cycling and blockade of system A glutamine transporters by MeAIB. Details appear in SI Appendix, Fig. S4. (B) Representative traces of mEPSC recordings in primary cortical neurons treated with 25 μM acivicin (24 h) and/or 25 mM MeAIB (2 h). (C and D) Distribution of mEPSC frequency and amplitude in cortical neurons treated with acivicin and/or MeAIB. (E and F) Cumulative probability plots of mEPSC frequency and amplitude. MeAIB decreased mEPSC frequency to a greater degree than acivicin, with both treatments having additive effects for presynaptic drive frequency. (p < 0.0001 by Steel-Dwass all pairs test.)
Our model may have mechanistic implications to interpret magnetic resonance spectroscopy studies in human subjects, in which total regional brain glutamate may be determined (63, 64), although it is unknown if this affects synaptic activity. Seven-Tesla (77T) proton magnetic resonance spectroscopy studies have shown that glutamate levels were significantly lower in first episode psychosis subjects, whereas glutamine levels were unaltered (65). This study also revealed lower levels of glutathione in the anterior cingulate cortex and thalamus, which supports the idea of origin of glutamate from glutathione (16).

We suggest that two drugs available for human use, sulforaphane, which increases glutathione, and pyroglutamate, which is converted to glutamate in the glutathione cycle, may be therapeutically beneficial. Sulforaphane (66) is a potent inducer of the Nrf2 transcription factor, has blood-brain barrier penetration (67), and might expand the size of the glutathione reservoir by our observation that it increases expression of GCL, the rate-limiting step in glutathione biosynthesis. Our recent study in human subjects revealed that sulforaphane elevates peripheral glutathione levels and those of other brain metabolites (68). Sulforaphane has also been reported to improve symptoms of autistic spectrum disorder (69). Pyroglutamate may be a promising therapeutic candidate for cognitive dysfunction in schizophrenia and other conditions with glutathione disturbances.

Materials and Methods
Cell Culture and Reagents. Dissociated cortical neuron cultures from Sprague-Dawley rats were prepared as described (74). Primary cortical neurons were maintained in Neurobasal medium (Life Technologies Corporation) supplemented with 1x B-27 (Life technologies).

Measurement of Glutathione. Total and oxidized glutathione were measured using 5-S-dithiobis (2-nitrobenzoic acid). Additional details of reagents and methods are available in SI Appendix.

ACKNOWLEDGMENTS. We thank Dr. Minori Koga for experimental support and discussions, Yukiko Lema for assistance in preparing the manuscript, and Brian Lee and Dr. David Linden for helpful discussions. Support was provided by National Institutes of Health, National Institute of Neurological Disorders and Stroke Grant K08NS057824; Johns Hopkins Brain Science Institute and National Association for Research on Schizophrenia and Depression Young Investigator Award (to T.W.S.); National Institute of Mental Health Grant MH-092443; National Institutes of Health Silvio O. Conte Center Grant MH-094268, NIH Grants MH-084018, MH-105660, and MH-107730; US Public Health Service Grant MH-18501 (to S.M.); and foundation supports from the Stanley Foundation and SR (A.S.).

2706